Synthesis of LRRK2-IN-1 (1)
g, 12.0 mmol) in dioxane (40 mL) was heated at 50˚C for 6 hours. After the reaction was complete as monitored by thin layer chromatography (TLC), the reaction solution was concentrated and the residue was purified by silica-gel column chromatography with ethyl acetate and hexane (1/20, v/v) A mixture of compound 2 (2.35 g, 6.98 mmol) and iron power (3.9 g, 69.8 mmol)
in acetic acid (100 mL) was heated at 50 ˚C for 9 hours. After the reaction was complete as monitored by reverse phase analytical liquid-chromatography electrospray mass spectrometry (LC-MS), the excess of iron was removed and the mixture was concentrated in vacuo. The resulting residue was poured into ice-water which resulted in a solid precipitate that was collected by filtration, washed with water and air dried to give the title compound 3 (1.55 g, 85% To a stirred suspension of compound 3 (688 mg, 2.64 mmol) and MeI (0.25 mL, 4.0 mmol) in dimethyl acetamide (DMA, 40.0 mL) was added NaH (360 mg, 60 % suspension in mineral oil) at -10 ˚C and the reaction was gradually warmed to 0 C . After the reaction was complete as monitored by LC-MS, the solution was poured into ice-water which resulted in a solid precipitate. The precipitate was collected by filtration, washed with water and air dried to give the title compound 4 (563 mg, 77% 
Scheme 2
To a stirred solution of 4-amino-3-methoxybenzoic acid (2.0 g, 12.0 mmol), 1- Tween (TBST). Previously characterised phospho-specific antibodies for the detection of LRRK2 S910 and S935 phosphorylation were used at a concentration of 1 µg/ml in blocking buffer overnight with the inclusion of 10 µg/ml dephosphorylated peptide 2 . Detection of immune-complexes was performed using a fluorophore conjugated rabbit anti-sheep secondary antibody (Molecular Probes) followed by visualisation and quantitation using an Odyssey LICOR. Digoxigenen (DIG) labelled 14-3-3 for use in overlay far western analysis was prepared as described in 6 . Membranes were incubated with DIG labelled 14-3-3 diluted to 0.5 µg/ml in 5% BSA in TBST overnight at 4 o C. DIG 14-3-3 was detected with HRP labelled anti-DIG Fab fragments (Roche). For GFP-LRRK2
expressing stable cell lines, 20 µg protein lysate was resolved on 8% polyacrylamide gels and immunoblotted for LRRK2 phosphorylated at S910 and LRRK2 phosphorylated at S935 as above. Total levels of GFP tagged LRRK2
were assessed using a sheep anti-GFP antibody.
In some instances phosphorylated S910 immunoblots were stripped with 1x re-blot plus (Millipore)
before reprobing with anti-GFP. 14-3-3 binding in these cell lines was determined 
Injection into mice.

LRRK2-IN-1 was dissolved in Captisol (Cydex Pharmaceuticals) and
administered by intraperitoneal injection into wild type male C57BL/6 mice at a dose of 100 mg/kg. Control mice were injected with an equal volume of Captisol.
At 1 and 2 h time points, mice were extinguished by cervical dislocation and kidney and brain tissue rapidly dissected and snap-frozen in liquid nitrogen.
Animal experiments were approved by the University of Dundee Ethics
Committee and performed under a U.K. Home office project license.
Statistical analysis.
GraphPad Prism was used to analyse quantitated immunoblots by one-way ANOVA. Significance between groups was determined using Tukey's post hoc test with significance accepted at p < 0.05.
Supplementary results
LRRK2-IN-1 selectivity profiling
The kinase selectivity of LRRK2-IN-1 was evaluated using the KINOMEscan TM methodology (Ambit Biosciences, San Diego, CA) 7, 8 , the KiNativ TM technology (ActivX Biosciences, San Diego, CA ) 9 , and standard radioactive-based enzymatic assays (Dundee profiling) 10 
PLK1 cellular activity of LRRK2-IN-1
For PLK1 we observed a 100-fold discrepancy between the observed ambit Kd 
Supplementary Table 1.
The combined kinase profiling hits with biochemical activities. Kinase hits from Ambit profiling with a score of less than 10% of the DMSO control at a concentration of 10 µM, ActivX profiling with higher than 50% inhibition at 1 µM, and Dundee profiling with greater than 50% inhibition at 1 µM are listed. The biochemical IC 50 values of hits were measured by Invitrogen Adapta ® , Z´-Lyte ® , Lantha-Screen ® assays (http://www.invitrogen.com/site/us/en/home/Productsand-Services/Services/ Screening-and-Profiling-Services/SelectScreen-Profilingervice/SelectScreen-Kinase-Profiling-Service.html) and Dundee radioactive-base enzyme assay 10 .
Kinase Label % Ctrl at 10 µM (Ambit) Fig. 5 LRRK2-IN-1 is a reversible inhibitor. (A) HEK 293 cells stably expressing wild type GFP-LRRK2 were treated with 1 µM LRRK2-IN-1 for the indicated time points. To determine LRRK2 rephosphorylation, inhibitor-containing media was removed 2 h after treatment, cells were washed twice and incubated with fresh media without inhibitor for the indicated time points. Cell lysates were subjected to immunoblotting for detection of LRRK2 phosphorylated at S910 and S935 and for total GFP-LRRK2. 14-3- Fig. 6 LRRK2-IN-1 does not induce dephosphorylation of kinase dead LRRK2. Stable cell lines expressing full length flag-tagged wild type and kinase inactive LRRK2 {D2017A] were treated with 1 µM LRRK2-IN-1 for 2 h. Phosphorylation of Ser910 and Ser935 was assessed by immunoblot. 14-3-3 binding was assessed by overlay assay. Immunoblot analysis was quantified by Odyssey LICOR with the top graph representing the ratio of LRRK2 S910 phosphorylation to total LRRK2 and the bottom graph representing the ratio of LRRK2 S935 phosphorylation to total LRRK2. The experiment was performed in duplicate and results are representative of two independent experiments. Data is presented as mean ± SEM. Supplementary Fig. 7 Effect of LRRK2-IN-1 in Swiss 3T3 cells. Endogenous LRRK2 was immunoprecipitated from 9 mg Swiss 3T3 cell lysate using anti-LRRK2 100-500 following treatment of cells with indicated doses of LRRK2-IN-1 for 2 h. Immunoprecipitates were subjected to immunoblot analysis and 14-3-3 overlay assay. Immunoprecipitations were performed in duplicate and results are representative of two independent experiments. Immunoblot analysis was quantified by Odyssey LICOR with the top graph representing the ratio of LRRK2 S910 phosphorylation to total LRRK2 and the bottom graph representing the ratio of LRRK2 S935 phosphorylation to total LRRK2. One-way ANOVA and Tukey's post hoc test were used to test for significant difference between LRRK2-IN-1 treatment and DMSO control. * = p < 0.05 compared to DMSO. Data are presented as mean ± SEM Supplementary Fig. 8 LRRK2-IN-1 Immunoblots for the detection of phosphorylated or total LRRK2 where scanned using the odyssey LICOR. Membranes were scanned from the 100kDa marker to the top (molecular weight of LRRK2 = 280 kDa). Experiments were performed in duplicate and results are representative of at least two independent experiments. Representative immunoblots were quantitated using the odyssey LICOR software. The top graph represents the ratio of LRRK2 phosphorylated at Ser910 to total LRRK2 whilst the bottom graphs represent the ratio of LRRK2 phosphorylated at Ser935 to total LRRK2. Data is presented as mean ± SEM. One-way ANOVA followed by Tukey's post hoc test was used to test for significant differences between LRRK2-IN-1 treated groups and DMSO control with * representing p < 0.05 compared to DMSO. 14-3-3 binding was assessed by overlay assay followed by detection with enhanced chemiluminescence. For the overlay assay membranes were again cut at the 100kDa marker. 
